Research

Research

Our response to “gremlin therapy” research that suggests pancreatic cancer can be reversed

30 June 2022

Our Head of Research at Pancreatic Cancer UK, Dr Chris MacDonald has provided commentary on new research from the Institute of Cancer Research which suggests that it could be possible to reverse a key process that enables pancreatic cancer cells to grow and spread in the body.

 

Our Research Involvement Network: Shaping the future of pancreatic cancer research

28 June 2022

Dr Naureen Starling is a Consultant Medical Oncologist at the Royal Marsden NHS Foundation Trust specialising in the treatment of gastrointestinal cancers, as well as researching new therapies.

Research

Presentations from Discovery and Translational Research Forum

Research

Our response to the mRNA pancreatic cancer vaccine trial

8 June 2022

Our Head of Research, Dr Chris MacDonald comments on the exciting trial results presented at the American Society of Clinical Oncology conference in Chicago.

Research

Pancreatic Cancer UK Discovery and Translational Research Forum, 13 & 14 June 2022

Research

New research project: what is pancreatic exocrine insufficiency and how can we diagnose it more quickly?

31 May 2022

Pancreatic exocrine insufficiency (PEI) occurs when the pancreas becomes unable to produce enough enzymes to break down food, and effectively causes the body to starve. The condition affects 60-90% of people with pancreatic cancer. 

Scotland

Pancreatic Cancer UK’s Research in Scotland: Changing the future of pancreatic cancer, 28th March 2022

link between diabetes and pancreatic cancer?
Research

What’s the link between diabetes and pancreatic cancer?

22 February 2022

Over 40% of people living with pancreatic cancer are diagnosed with diabetes. We don't know why or how this happens, but understanding this link between diabetes and pancreatic cancer could hold a vital key to earlier diagnosis.

Research

Pancreatic Cancer UK Discovery and Translational Research Forum, 13 & 14 June 2022

Research

Research Involvement Network opportunity: Join a Patient Advisory Panel and help update the Quality of Life questionnaire for pancreatic cancer

SABR treatment, Pancreatic cancer
Treatments

Introducing SABR treatment for pancreatic cancer

26 January 2022

In Autumn 2020, Pancreatic Cancer UK helped to submit a proposal to NHS England, asking them to commission a type of radiotherapy called SABR (Stereotactic Ablative Body Radiotherapy), for people with locally advanced pancreatic cancer (LAPC). Now, SABR treatment has been commissioned for rollout in England, thanks to a group of healthcare professionals and Pancreatic Cancer UK's Research Involvement Network (RIN).

Research

NEW Career Progression Fellowships

Find out more about the Pancreatic Cancer UK Research Innovation Fund and how you can apply.